{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T10:14:43Z","timestamp":1779963283941,"version":"3.53.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KWF; IKNL 2022-14701"],"award-info":[{"award-number":["KWF; IKNL 2022-14701"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Insights Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Guidelines recommend MRI before prostate biopsy in men with suspected prostate cancer (PCa). However, real-world data on clinical use are scarce. This study aims to provide comprehensive insight into the nationwide use of pre-biopsy MRI across the Netherlands.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      Men with biopsy-proven primary PCa diagnosed between 2019 and 2023, were identified through the Netherlands Cancer Registry (main cohort;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200950,987). A historical cohort included similar cases from 2015 to 2016 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095183). Four MRI-related periods were defined: historical (2015\u20132016), pre-implementation (2019), implementation (2020), and post-implementation (2021\u20132023). Mixed-effects logistic regression analyses assessed factors associated with pre-biopsy MRI use and heterogeneity across periods. Inter-hospital variation was quantified using case-mix (age, PSA, clinical disease stage) adjusted hospital-specific probabilities.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Pre-biopsy MRI use increased from 17 to 74% between 2015 and 2023. Across all periods (main cohort), men over 70 and those with a PSA\u2009&gt;\u200950\u2009\u00b5g\/L or cT3-4 disease were significantly less likely to undergo pre-biopsy MRI than younger men, those with PSA\u2009&lt;\u200910\u2009\u00b5g\/L, or cT1 disease, respectively. Heterogeneity in effect size across periods was observed for all factors except age. Inter-hospital variation was present in all MRI-related periods, although it significantly decreased over time. Estimated 75% midrange rates varied from 9.7\u201386% (pre-implementation) to 62\u201388% (post-implementation).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pre-biopsy MRI use in PCa diagnosis has markedly increased and has become more consistent across hospitals. Over time, its use became more targeted, focusing on patients without signs of advanced disease, in accordance with EAU guidelines recommendations. Continued efforts to standardize MRI use may improve equity and optimize patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Critical relevance statement<\/jats:title>\n                    <jats:p>This study evaluates the nationwide implementation of pre-biopsy MRI in PCa diagnosis, revealing increased and more targeted use, demonstrating consistency across hospitals, and providing insights to guide standardization and optimize patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Comprehensive population-level data on the uptake of pre-biopsy MRI after implementing guideline recommendations are essential for clinical practice evaluations on a national level.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>In the Netherlands, these data show an increase in the uptake of pre-biopsy MRI over time, demonstrate consistent patterns across hospitals, and illustrate a shift towards use in patients without advanced disease, aligning with EAU guidelines recommendations.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Ongoing efforts to implement and standardize pre-biopsy MRI use in routine clinical practice are critical to promote equity and optimize patient outcomes on a population-based level.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13244-026-02282-9","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T09:47:28Z","timestamp":1779961648000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Increasing and more consistent use of pre-biopsy MRI in prostate cancer diagnosis: insights from a population-based study in the Netherlands"],"prefix":"10.1186","volume":"17","author":[{"given":"C. C.","family":"Loeff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9804-0603","authenticated-orcid":false,"given":"I. G.","family":"Schoots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. J.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. E.","family":"Oprea-Lager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Al-Uwini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. A. L. M.","family":"Kiemeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. M.","family":"van Oort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. K. H.","family":"Aben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. L.","family":"Heesterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the ADMINISTRATE Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. J.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. M.","family":"van Oort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"2282_CR1","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378:1767\u20131777","journal-title":"N Engl J Med"},{"key":"2282_CR2","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.eururo.2018.11.023","volume":"75","author":"M van der Leest","year":"2019","unstructured":"van der Leest M, Cornel E, Isra\u00ebl B et al (2019) Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-na\u00efve men with elevated prostate-specific antigen: a large prospective multicenter clinical study. Eur Urol 75:570\u2013578","journal-title":"Eur Urol"},{"key":"2282_CR3","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1470-2045(18)30569-2","volume":"20","author":"O Rouvi\u00e8re","year":"2019","unstructured":"Rouvi\u00e8re O, Puech P, Renard-Penna R et al (2019) Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol 20:100\u2013109","journal-title":"Lancet Oncol"},{"key":"2282_CR4","doi-asserted-by":"crossref","unstructured":"Cornford P, van den Bergh RCN, Briers E et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol 86:148\u2013163","DOI":"10.1016\/j.eururo.2024.03.027"},{"key":"2282_CR5","unstructured":"Wagensveld I, Isra\u00ebl B, de Reijke TM et al (2020) Module diagnostische prostaat MRI voor de richtlijn prostaatcarcinoom. Nederlandse Vereniging voor Urologie"},{"key":"2282_CR6","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1148\/radiol.2016152542","volume":"280","author":"AB Rosenkrantz","year":"2016","unstructured":"Rosenkrantz AB, Ginocchio LA, Cornfeld D et al (2016) Interobserver reproducibility of the PI-RADS version 2 Lexicon: a multicenter study of six experienced prostate radiologists. Radiology 280:793\u2013804","journal-title":"Radiology"},{"key":"2282_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1148\/radiol.2020190646","volume":"296","author":"AC Westphalen","year":"2020","unstructured":"Westphalen AC, McCulloch CE, Anaokar JM et al (2020) Variability of the positive predictive value of PI-RADS for prostate MRI across 26 centers: experience of the society of abdominal radiology prostate cancer disease-focused panel. Radiology 296:76\u201384","journal-title":"Radiology"},{"key":"2282_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euros.2025.01.004","volume":"73","author":"TP Scherer","year":"2025","unstructured":"Scherer TP, Menges D, Bieri U et al (2025) Impact of prebiopsy multiparametric magnetic resonance imaging on prostate cancer detection in Switzerland. Eur Urol Open Sci 73:1\u20137","journal-title":"Eur Urol Open Sci"},{"key":"2282_CR9","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/bco2.214","volume":"4","author":"ES Haug","year":"2023","unstructured":"Haug ES, Myklebust T, Julieb\u00f8-Jones P et al (2023) Impact of prebiopsy MRI on prostate cancer staging: results from the Norwegian Prostate Cancer Registry. BJUI Compass 4:331\u2013338","journal-title":"BJUI Compass"},{"key":"2282_CR10","unstructured":"Integraal Kankercentrum Nederland (IKNL). ProZIB: evaluatie van de kwaliteit van prostaatkankerzorg. Utrecht: IKNL; 2014-2019 (cited 2026 Apr 13). Available from: https:\/\/iknl.nl\/projecten\/prozib"},{"key":"2282_CR11","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.ijrobp.2010.07.030","volume":"78","author":"HZ Montes","year":"2010","unstructured":"Montes HZ (2010) TNM classification of malignant tumors, 7th edition. Int J Radiat Oncol Biol Phys 78:1278","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2282_CR12","unstructured":"Gospodarowicz MK, Wittekind C, Brierley JD (eds) TNM classification of malignant tumours, 8th edn. Wiley-Blackwell, p 272"},{"key":"2282_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.euo.2019.06.001","volume":"3","author":"H van der Poel","year":"2020","unstructured":"van der Poel H, van der Kwast T, Aben K, Mottet N, Mason M (2020) Imaging and T Category for prostate cancer in the 8th edition of the Union for International Cancer Control TNM classification. Eur Urol Oncol 3:563\u2013564","journal-title":"Eur Urol Oncol"},{"key":"2282_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373\u2013383","journal-title":"J Chronic Dis"},{"key":"2282_CR15","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1136\/bmjqs-2018-009165","volume":"28","author":"G Abel","year":"2019","unstructured":"Abel G, Elliott MN (2019) Identifying and quantifying variation between healthcare organisations and geographical regions: using mixed-effects models. BMJ Qual Saf 28:1032\u20131038","journal-title":"BMJ Qual Saf"},{"key":"2282_CR16","unstructured":"Borre MBL, Elversang J, Hansen S et al (2023) DaProCa: dansk prostata cancer database. Clin Epidemiol. https:\/\/ducg.dk\/fileadmin\/ingen_mappe_valgt\/Prostata_rapport_2022_version_til_offentliggoerelse_12062023_final.pdf"},{"key":"2282_CR17","doi-asserted-by":"publisher","first-page":"e2330233","DOI":"10.1001\/jamanetworkopen.2023.30233","volume":"6","author":"D Robinson","year":"2023","unstructured":"Robinson D, Abdulkareem R, Nasrollah D et al (2023) Frequency of biopsy and tumor grade before vs after introduction of prostate magnetic resonance imaging. JAMA Netw Open 6:e2330233","journal-title":"JAMA Netw Open"},{"key":"2282_CR18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41391-022-00543-4","volume":"26","author":"MR Siddiqui","year":"2023","unstructured":"Siddiqui MR, Ansbro B, Shah PV et al (2023) Real-world use of MRI for risk stratification prior to prostate biopsy. Prostate Cancer Prostatic Dis 26:353\u2013359","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2282_CR19","doi-asserted-by":"publisher","first-page":"4090","DOI":"10.1007\/s00261-020-02657-6","volume":"45","author":"C Washington","year":"2020","unstructured":"Washington C, Deville C Jr (2020) Health disparities and inequities in the utilization of diagnostic imaging for prostate cancer. Abdom Radiol (NY) 45:4090\u20134096","journal-title":"Abdom Radiol (NY)"},{"key":"2282_CR20","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.euo.2018.11.009","volume":"2","author":"J Morote","year":"2019","unstructured":"Morote J, Celma A, Roche S et al (2019) Who benefits from multiparametric magnetic resonance imaging after suspicion of prostate cancer? Eur Urol Oncol 2:664\u2013669","journal-title":"Eur Urol Oncol"},{"key":"2282_CR21","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.urolonc.2023.05.003","volume":"41","author":"J Morote","year":"2023","unstructured":"Morote J, Picola N, Paesano N et al (2023) Are magnetic resonance imaging and targeted biopsies needed in men with serum prostate-specific antigen over 10 ng\/ml and an abnormal digital rectal examination?. Urol Oncol 41:299\u2013301","journal-title":"Urol Oncol"},{"key":"2282_CR22","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/bco2.211","volume":"4","author":"J Morote","year":"2023","unstructured":"Morote J, Triquell M, Campistol M, Abascal JM, Servian P, Trilla E (2023) Stratifying the initial prostate cancer suspicion to avoid magnetic resonance exams by sequencing men according to serum prostate-specific antigen, digital rectal examination and the prostate-specific antigen density based on digital rectal prostate volume category. BJUI Compass 4:266\u2013268","journal-title":"BJUI Compass"},{"key":"2282_CR23","unstructured":"Nederlandse Vereniging voor Urologie (2019) Module PSMA PET\/CT voor de richtlijn prostaatcarcinoom. Utrecht. Available from: https:\/\/richtlijnendatabase.nl\/richtlijn\/prostaatcarcinoom\/diagnostiek.html"},{"key":"2282_CR24","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.euo.2022.04.006","volume":"5","author":"T Kawada","year":"2022","unstructured":"Kawada T, Yanagisawa T, Rajwa P et al (2022) Diagnostic performance of prostate-specific membrane antigen positron emission tomography-targeted biopsy for detection of clinically significant prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol 5:390\u2013400","journal-title":"Eur Urol Oncol"},{"key":"2282_CR25","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/bju.16167","volume":"132","author":"YJL Bodar","year":"2023","unstructured":"Bodar YJL, Boev\u00e9 LMS, van Leeuwen PJ et al (2023) Using prostate-specific membrane antigen positron-emission tomography to guide prostate biopsies and stage men at high-risk of prostate cancer. BJU Int 132:705\u2013712","journal-title":"BJU Int"},{"key":"2282_CR26","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.eururo.2022.03.003","volume":"82","author":"IM Wagensveld","year":"2022","unstructured":"Wagensveld IM, Osses DF, Groenendijk PM et al (2022) A prospective multicenter comparison study of risk-adapted ultrasound-directed and magnetic resonance imaging-directed diagnostic pathways for suspected prostate cancer in biopsy-na\u00efve men. Eur Urol 82:318\u2013326","journal-title":"Eur Urol"},{"key":"2282_CR27","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/bju.15562","volume":"129","author":"B Isra\u00ebl","year":"2022","unstructured":"Isra\u00ebl B, Immerzeel J, van der Leest M et al (2022) Clinical implementation of pre-biopsy magnetic resonance imaging pathways for the diagnosis of prostate cancer. BJU Int 129:480\u2013490","journal-title":"BJU Int"},{"key":"2282_CR28","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/bju.15899","volume":"131","author":"D Eldred-Evans","year":"2023","unstructured":"Eldred-Evans D, Connor MJ, Bertoncelli Tanaka M et al (2023) The rapid assessment for prostate imaging and diagnosis (RAPID) prostate cancer diagnostic pathway. BJU Int 131:461\u2013470","journal-title":"BJU Int"},{"key":"2282_CR29","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S1470-2045(24)00220-1","volume":"25","author":"A Saha","year":"2024","unstructured":"Saha A, Bosma JS, Twilt JJ et al (2024) Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study. Lancet Oncol 25:879\u2013887","journal-title":"Lancet Oncol"},{"key":"2282_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.euo.2020.02.005","volume":"3","author":"A Stabile","year":"2020","unstructured":"Stabile A, Giganti F, Kasivisvanathan V et al (2020) Factors influencing variability in the performance of multiparametric magnetic resonance imaging in detecting clinically significant prostate cancer: a systematic literature review. Eur Urol Oncol 3:145\u2013167","journal-title":"Eur Urol Oncol"},{"key":"2282_CR31","doi-asserted-by":"crossref","unstructured":"Twilt JJ, Saha A, Bosma JS et al (2024) Evaluating biparametric versus multiparametric magnetic resonance imaging for diagnosing clinically significant prostate cancer: an international, paired, noninferiority, confirmatory observer study. Eur Urol 87:240\u2013250","DOI":"10.1016\/j.eururo.2024.09.035"},{"key":"2282_CR32","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1007\/s00330-021-08407-6","volume":"32","author":"LK Bittencourt","year":"2022","unstructured":"Bittencourt LK, Guricova K, Zucker I, Durieux JC, Schoots IG (2022) Risk-based MRI-directed diagnostic pathway outperforms non-risk-based pathways in suspected prostate cancer biopsy-na\u00efve men: a large cohort validation study. Eur Radiol 32:2330\u20132339","journal-title":"Eur Radiol"},{"key":"2282_CR33","volume":"31","author":"DV Deukeren","year":"2022","unstructured":"Deukeren DV, Heesterman BL, Roelofs L et al (2022) Impact of the COVID-19 outbreak on prostate cancer care in the Netherlands. Cancer Treat Res Commun 31:100553","journal-title":"Cancer Treat Res Commun"},{"key":"2282_CR34","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.juro.2011.12.015","volume":"187","author":"D Liu","year":"2012","unstructured":"Liu D, Lehmann HP, Frick KD, Carter HB (2012) Active surveillance versus surgery for low risk prostate cancer: a clinical decision analysis. J Urol 187:1241\u20131246","journal-title":"J Urol"}],"container-title":["Insights into Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-026-02282-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13244-026-02282-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-026-02282-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T09:47:35Z","timestamp":1779961655000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13244-026-02282-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2282"],"URL":"https:\/\/doi.org\/10.1186\/s13244-026-02282-9","relation":{},"ISSN":["1869-4101"],"issn-type":[{"value":"1869-4101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Privacy Review Board of the NCR (K23.104).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"143"}}